Plasma

1 mL plasma from a Special Z preservative collection tube obtained from reference laboratory.

Keep on ice and deliver to laboratory immediately.

1 week upon receipt at reference laboratory

Long-acting repeatable (LAR) dose-response levels: mean octreotide level ± 2SD for patients on octreotide LAR for 3 or more months (steady-state). The following represent trough levels measured immediately before an injection of LAR.

Octreotide administered by pump:
60 mg/month: 10,000 pg/ml +/- 2,500 pg/mL
30 mg/month: 5,000 pg/ml +/- 2,500 pg/mL

Octreotide administered as Sandostatin(R) LAR:
120 mg/month: 9,000 pg/ml +/- 2,000 pg/mL
60 mg/month: 5,000 pg/ml +/- 2,000 pg/mL
30 mg/month: 2,500 pg/ml +/- 1,500 pg/mL

Octreotide administered by subcutaneous injection:
Measurement of plasma octreotide is not recommended for individuals using multiple daily octreotide injections due to the short half life of octreotide in the plasma (approximately 90-120 minutes)

Contact Commercial Mailouts at 356-8593, Specimen Control at 356-3527 or the Clinical Cancer Center at 356-4200 to obtain collection tubes for this testing. No other specimen collection container is acceptable by the reference laboratory.

This test is useful only for those patients being treated with octreotide acetate. No special preparation is needed for this test. For optimal results, blood for this test should be drawn immediately before the patient's next injection of octreotide LAR (trough levels).

Octreotide is measured by direct radioimmunoassay. There is no cross- reactivity with native somatostatin-14 or somatostatin-28. The also is no cross-reactivity with lanreotide, and this test should not be used to measure blood levels of this drug.

83519

See Additional Information:
Specimens Requiring Immediate Delivery